Newsroom

Immunexpress Supports World Sepsis Day 2015

September 10, 2015

Call for Action on Sept. 13 Includes Awareness, Education and Funding Initiatives to Help Reverse Global Increase in Numbers of Deaths from Sepsis Video Interviews on the Immunexpress Website Highlight the Need for Faster Diagnosis of Sepsis SEATTLE, Sept. 10, 2015 – Immunexpress, Inc., a molecular diagnostic company committed...

Immunexpress to Present Data on the Early Diagnosis of Sepsis with SeptiCyte™ LAB at the Next Generation Diagnostics Summit

August 12, 2015

SEATTLE, Aug. 12, 2015 – Immunexpress, Inc. today announced that Dr. Therese Seldon, Vice President of Operations, will present data on the utility of its SeptiCyte® Lab test to aid in the clinical assessment of sepsis in critical care patients at the Next Generation Diagnostics Summit on Aug. 19 in...

Immunexpress to Present Data on Utility of SeptiCyte™ LAB for Diagnosing Sepsis at the Pathology Diagnostics Conference

June 4, 2015

Immunexpress to Present Data on Utility of SeptiCyte™ Lab for Diagnosing Sepsis at the Pathology Diagnostics Conference SeptiCyte™ Lab Quantifies Host Molecular Markers to Aid Physicians in the Diagnosis of Sepsis in Critical Care Patients SEATTLE, June 4, 2015 – Immunexpress, Inc. today announced that Dr. Antony Rapisarda, Director Medical...

Immunexpress to Submit Molecular ‘Immune Response’ Sepsis Assay to FDA in May

April 30, 2015

Immunexpress may finally be close to marketing a clinical test in the US. Having just wrapped up a key clinical trial of its first sepsis assay in around 200 ICU patients, the company plans to submit the test in May to the US Food and Drug Administration and hopes it can...

Immunexpress vying for FDA clearance of its sepsis test

April 6, 2015

When it comes right down to detecting sepsis most diagnostics companies use methods to identify the pathogen. But therein lies the issue with looking for the pathogen, because it has to be in the blood sample or the fluid sample to start with, otherwise a clinician can't find. That's where...

Immunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour

April 3, 2015

Seattle diagnostics company Immunexpress is working to whittle sepsis screening time down to an hour – and is in the midst of a $40 million Series C to do so.

Immunexpress Receives Early Stage Commercialisation Support to Further Develop SeptiCyte® PLUS

February 18, 2014

Immunexpress receives Early Stage Commercialisation support to further develop SeptiCyte®PLUS — designed to diagnose sepsis accurately within a clinically relevant timeframe. BRISBANE, Australia (February 18, 2014) – Today, Immunexpress Group (Immunexpress) announced it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD...

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection

October 13, 2013

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection April 1, 2013 – Today, Immunexpress Group announced the granting of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment” in the European Union (EU). This patent...

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients

April 10, 2013

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients The MARS Consortium is one of the largest collaborations of academic and industry partners dedicated solely to improving sepsis outcomes SEATTLE, United States / EINDHOVEN, The Netherlands (April 10, 2013) –Today, the Immunexpress Group announced its collaboration...

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection

November 21, 2012

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection SEATTLE, United States (November 21, 2012) – Today, Immunexpress Group announced the granting in the United States (U.S.) of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment.”...

Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis

June 20, 2011

Sutherland et al., Critical Care | A novel molecular biomarker test based on a panel of 42-gene expression markers has demonstrated a clinically relevant sensitivity and specificity profile, and has the capacity for early detection of sepsis via the monitoring of critical care patients.